##### Table of Contents



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549
 FORM 10-K/A
 (Amendment No. 1)
 þ
    
    ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 For the year ended December 31, 2008.
 Or
 o
    
    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 For the transition period from  to .
 Commission
file number 001-14471
 MEDICIS PHARMACEUTICAL CORPORATION
  Delaware
    
    52-1574808(State or other jurisdiction
    
    (I.R.S. Employer Identification No.)of incorporation or organization)
 7720 N. Dobson Road, Scottsdale, Arizona
    
    85256-2740(Address of principal executive office)
    
    (Zip Code)Registrants telephone number, including area code:
    
    (602) 808-8800
  New York Stock Exchange
    
    Preference Share Purchase Rights(Name of each exchange on which
    
    (Title of each Class)registered)
 þ o
 o þ
 þ o
 o o
 o
  Large accelerated filer þ
    
    Accelerated filer o
    
    Non-accelerated filer   o
(Do not check if a smaller reporting company)
    
    Smaller reporting company o
 o þ




---



TABLE OF CONTENTS  PART IVItem 15. Exhibits, Financial Statement SchedulesSIGNATURESEX-10.61EX-31.1EX-31.2    Table of Contents  Explanatory Note
  2




---



##### Table of Contents



PART IV
 
    Exhibit No.
    
    Description2.1
    
    
    Agreement of Merger by and between the Company, Medicis Acquisition Corporation and GenDerm
Corporation, dated November 28, 1997 (11)2.2
    
    
    Agreement of Plan of Merger, dated as of October 1, 2001, by and among the Company, MPC
Merger Corp. and Ascent Pediatrics, Inc. (17)2.3
    
    
    Agreement and Plan of Merger by and among the Company, Donatello, Inc., and LipoSonix, Inc.
dated June 16, 2008(49)3.1
    
    
    Certificate of Incorporation of the Company, as amended (23)3.2
    
    
    Amended and Restated By-Laws of the Company (43)4.1
    
    
    Amended and Restated Rights Agreement, dated as of August 17, 2005, between the Company and
Wells Fargo Bank, N.A., as Rights Agent(26)4.2
    
    
    Indenture, dated as of August 19, 2003, by and between the Company, as issuer, and Deutsche
Bank Trust Company Americas, as trustee (23)4.3
    
    
    Indenture, dated as of June 4, 2002, by and between the Company, as issuer, and Deutsche Bank
Trust Company Americas, as trustee.(19)4.4
    
    
    Supplemental Indenture dated as of February 1, 2005 to Indenture dated as of August 19, 2003
between the Company and Deutsche Bank Trust Company Americas as Trustee (25)4.5
    
    
    Registration Rights Agreement, dated as of June 4, 2002, by and between the Company and
Deutsche Bank Securities Inc. (19)4.6
    
    
    Form of specimen certificate representing Class A common stock (1)10.1
    
    
    Asset Purchase Agreement among the Company, Ascent Pediatrics, Inc., BioMarin Pharmaceutical
Inc., and BioMarin Pediatrics Inc., dated April 20, 2004 (23)10.2
    
    
    Merger Termination Agreement, dated as of December 13, 2005, by and among the Company,
Masterpiece Acquisition Corp., and Inamed Corporation(31)10.3
    
    
    Securities Purchase Agreement among the Company, Ascent Pediatrics, Inc., BioMarin
Pharmaceutical Inc. and BioMarin Pediatrics Inc., dated May 18, 2004 (23)10.4
    
    
    Termination Agreement dated October 19, 2005 between the Company and Michael A.
Pietrangelo(28)10.5
    
    
    License Agreement among the Company, Ascent Pediatrics, Inc. and BioMarin Pediatrics Inc.,
dated May 18, 2004 (23)10.6
    
    
    Medicis Pharmaceutical Corporation 1995 Stock Option Plan (incorporated by
reference to Exhibit C to the definitive Proxy Statement for the 1995 Annual
Meeting of Shareholders previously filed with the SEC, File No. 0-18443)10.7(a)
    
    Employment Agreement between the Company and Jonah Shacknai, dated
July 24, 1996 (8)10.7(b)
    
    Amendment to Employment Agreement by and between the Company and
Jonah Shacknai, dated April 1, 1999 (15)10.7(c)
    
    Amendment to Employment Agreement by and between the Company and
Jonah Shacknai, dated February 21, 2001 (15)10.7(d)
    
    Third Amendment, dated December 30, 2005, to Employment Agreement between the Company and
Jonah Shacknai(32)10.8
    
    
    Medicis Pharmaceutical Corporation 2001 Senior Executive Restricted Stock Plan(30)10.9(a)
    
    Medicis Pharmaceutical Corporation 2002 Stock Option Plan (20)10.9(b)
    
    Amendment No. 1 to the Medicis Pharmaceutical Corporation 2002 Stock Option Plan, dated
August 1, 2005(29)10.10(a)
    
    Medicis Pharmaceutical Corporation 2004 Stock Incentive Plan(27)10.10(b)
    
    Amendment No. 1 to the Medicis Pharmaceutical Corporation 2004 Stock Option Plan, dated
August 1, 2005(29)10.11(a)
    
    Medicis Pharmaceutical Corporation 1998 Stock Option Plan(33)
 3




---



##### Table of Contents



Exhibit No.
    
    Description10.11
    (b)
    
    Amendment No. 1 to the Medicis Pharmaceutical Corporation 1998 Stock Option Plan, dated
August 1, 2005(29)10.11
    (c)
    
    Amendment No. 2 to the Medicis Pharmaceutical Corporation 1998 Stock Option Plan, dated
September 30, 2005(29)10.12
    (a)
    
    Medicis Pharmaceutical Corporation 1996 Stock Option Plan(34)10.12
    (b)
    
    Amendment No. 1 to the Medicis Pharmaceutical Corporation 1996 Stock Option Plan, dated
August 1, 2005(29)10.13
    
    
    Waiver Letter dated March 18, 2005 between the Company and Q-Med AB(27)10.14
    
    
    Supply Agreement, dated October 21, 1992, between Schein Pharmaceutical and the Company
(2)10.15
    
    
    Amendment to Manufacturing and Supply Agreement, dated March 2, 1993, between
Schein Pharmaceutical and the Company (3)10.16
    (a)
    
    Credit and Security Agreement, dated August 3, 1995, between the Company and
Norwest Business Credit, Inc. (5)10.16
    (b)
    
    First Amendment to Credit and Security Agreement, dated May 29, 1996,
between the Company and Norwest Bank Arizona, N.A. (8)10.16
    (c)
    
    Second Amendment to Credit and Security Agreement, dated November 22, 1996,
by and between the Company and Norwest Bank Arizona, N.A. as successor-in-interest
to Norwest Business Credit, Inc. (10)10.16
    (d)
    
    Third Amendment to Credit and Security Agreement, dated November 22, 1998, by
and between the Company and Norwest Bank Arizona, N.A., as successor-in-interest
to Norwest Business Credit, Inc. (12)10.16
    (e)
    
    Fourth Amendment to Credit and Security Agreement, dated November 22, 2000,
by and between the Company and Wells Fargo Bank Arizona, N.A., formerly
known as Norwest Bank Arizona, N.A., as successor-in-interest to Norwest Business
Credit, Inc.(16)10.16
    (f)
    
    Fifth Amendment to Credit and Security Agreement, dated November 22, 2002, by and between the
Company and Wells Fargo Bank Arizona, N.A., formerly known as Norwest Bank Arizona, N.A., as
successor-in-interest to Norwest Business Credit, Inc. (23)10.17
    (a)
    
    Patent Collateral Assignment and Security Agreement, dated August 3, 1995, by
the Company to Norwest Business Credit, Inc. (6)10.17
    (b)
    
    First Amendment to Patent Collateral Assignment and Security Agreement, dated
May 29, 1996, by the Company to Norwest Bank Arizona, N.A. (8)10.17
    (c)
    
    Amended and Restated Patent Collateral Assignment and Security Agreement, dated
November 22, 1998, by the Company to Norwest Bank Arizona, N.A. (12)10.18
    (a)
    
    Trademark Collateral Assignment and Security Agreement, dated August 3, 1995,
by the Company to Norwest Business Credit, Inc. (7)10.18
    (b)
    
    First Amendment to Trademark Collateral Assignment and Security Agreement, dated
May 29, 1996, by the Company to Norwest Bank Arizona, N.A. (8)10.18
    (c)
    
    Amended and Restated Trademark, Tradename, and Service Mark Collateral
Assignment and Security Agreement, dated November 22, 1998, by the Company
to Norwest Bank Arizona, N.A. (12)10.19
    
    
    Assignment and Assumption of Loan Documents, dated May 29, 1996, from
Norwest Business Credit, Inc., to and by Norwest Bank Arizona, N.A. (8)10.20
    
    
    Multiple Advance Note, dated May 29, 1996, from the Company to Norwest Bank
Arizona, N.A. (8)10.21
    
    
    Asset Purchase Agreement dated November 15, 1998, by and among the Company and
Hoechst Marion Roussel, Inc., Hoechst Marion Roussel Deutschland GMHB and
Hoechst Marion Roussel, S.A. (12)10.22
    
    
    License and Option Agreement dated November 15, 1998, by and among the Company
and Hoechst Marion Roussel, Inc., Hoechst Marion Roussel Deutschland GMBH and
Hoechst Marion Roussel, S.A. (12)10.23
    
    
    Loprox Lotion Supply Agreement dated November 15, 1998, by and between the
Company and Hoechst Marion Roussel, Inc. (12)10.24
    
    
    Supply Agreement dated November 15, 1998, by and between the Company and
Hoechst Marion Roussel Deutschland GMBH (12)10.25
    
    
    Asset Purchase Agreement effective January 31, 1999, between the Company and
Bioglan Pharma Plc (14)10.26
    
    
    Stock Purchase Agreement by and among the Company, Ucyclyd Pharma, Inc. and
Syed E. Abidi, William Brusilow, Susan E. Brusilow and Norbert L. Wiech, dated
April 19, 1999 (14)
 4




---



##### Table of Contents



Exhibit No.
    
    Description10.27
    
    
    Asset Purchase Agreement by and between the Company and Bioglan Pharma Plc,
dated June 29, 1999 (14)10.28
    
    
    Asset Purchase Agreement by and among The Exorex Company, LLC, Bioglan
Pharma Plc, the Company and IMX Pharmaceuticals, Inc., dated June 29, 1999 (16)10.29
    
    
    Medicis Pharmaceutical Corporation Executive Retention Plan (14)10.30
    
    
    Asset Purchase Agreement between Warner Chilcott, plc and the Company, dated
September 14, 1999(14)10.31
    (a)
    
    Share Purchase Agreement between Q-Med International B.V. and Startskottet 21914
AB (under proposed change of name to Medicis Sweden Holdings AB), dated
February 10, 2003(21)10.31
    (b)
    
    Amendment No. 1 to Share Purchase Agreement between Q-Med International
B.V. and Startskottet 21914 AB (under proposed change of name to Medicis Sweden
Holdings AB), dated March 7, 2003(21)10.32
    
    
    Supply Agreement between Q-Med AB and the Company,
dated March 7, 2003(21)10.33
    
    
    Amended and Restated Intellectual Property Agreement between Q-Med AB and HA
North American Sales AB, dated March 7, 2003(21)10.34
    
    
    Supply Agreement between Medicis Aesthetics Holdings Inc., a wholly owned subsidiary of the
Company, and Q-Med AB, dated July 15, 2004 (23) Portions of this exhibit
(indicated by asterisks) have been omitted pursuant to a request for confidential treatment
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934.10.35
    
    
    Intellectual Property License Agreement between Q-Med AB and Medicis Aesthetics Holdings
Inc., dated July 15, 2004 (23) Portions of this exhibit (indicated by asterisks)
have been omitted pursuant to a request for confidential treatment pursuant to Rule 24b-2
under the Securities Exchange Act of 1934.10.36
    
    
    Note Agreement, dated as of October 1, 2001, by and among Ascent Pediatrics, Inc., the
Company, Furman Selz Investors II L.P., FS Employee Investors LLC, FS Ascent Investments LLC,
FS Parallel Fund L.P., BancBoston Ventures Inc. and Flynn Partners (17)10.37
    
    
    Voting Agreement, dated as of October 1, 2001, by and among the Company, MPC Merger Corp., FS
Private Investments LLC, Furman Selz Investors II L.P., FS Employee Investors LLC, FS Ascent
Investments LLC and FS Parallel Fund L.P. (17)10.38
    
    
    Exclusive Remedy Agreement, dated as of October 1, 2001, by and among the Company, Ascent
Pediatrics, Inc., FS Private Investments LLC, Furman Selz Investors II L.P., FS Employee
Investors LLC, FS Ascent Investments LLC and FS Parallel Fund L.P., BancBoston Ventures Inc.,
Flynn Partners, Raymond F. Baddour, Sc.D., Robert E. Baldini, Medical Science Partners L.P.
and Emmett Clemente, Ph.D. (17)10.39
    
    
    Medicis Pharmaceutical Corporation 1992 Stock Option Plan(35)10.40
    
    
    Form of Stock Option Agreement for Medicis Pharmaceutical Corporation 2004 Stock Incentive
Plan(36)10.41
    
    
    Form of Restricted Stock Agreement for Medicis Pharmaceutical Corporation 2004 Stock
Incentive Plan(36)10.42
    
    
    Letter Agreement dated as of March 13, 2006 among Medicis Pharmaceutical Corporation,
Aesthetica Ltd., Medicis Aesthetics Holdings Inc., Ipsen S.A. and Ipsen Ltd.(37)10.43
    *
    
    Development and Distribution Agreement by and between Aesthetica, Ltd. and Ipsen, Ltd.(38)10.44
    *
    
    Trademark License Agreement by and between Aesthetica, Ltd. and Ipsen, Ltd.(38)10.45
    *
    
    Trademark Assignment Agreement by and between Aesthetica, Ltd. and Ipsen, Ltd.(38)10.46
    (a)
    
    Medicis 2006 Incentive Award Plan(39)10.46
    (b)
    
    Amendment to the Medicis 2006 Incentive Award Plan, dated July 10, 2006(41)10.46
    (c)
    
    Amendment No. 2 to the Medicis 2006 Incentive Award Plan, dated April 11, 2007(46)10.46
    (d)
    
    Amendment No. 3 to the Medicis 2006 Incentive Award Plan, dated April 16, 2007(45)10.46
    (e)
    
    Form of Stock Option Agreement for Medicis Pharmaceutical Corporation 2006 Incentive Award
Plan(48)10.46
    (f)
    
    Form of Restricted Stock Agreement for Medicis Pharmaceutical Corporation 2006 Incentive
Award Plan(48)10.47
    
    
    Employment Agreement, dated July 25, 2006, between Medicis Pharmaceutical Corporation and
Mark A. Prygocki, Sr.(40)
 5




---



##### Table of Contents



Exhibit No.
    
    Description10.48
    
    
    Employment Agreement, dated July 25, 2006, between Medicis Pharmaceutical Corporation and
Mitchell S. Wortzman, Ph.D.(40)10.49
    
    
    Employment Agreement, dated July 25, 2006, between Medicis Pharmaceutical Corporation and
Richard J. Havens(40)10.50
    
    
    Employment Agreement, dated July 27, 2006, between Medicis Pharmaceutical Corporation and
Jason D. Hanson(40)10.51
    *
    
    Office Sublease by and between Apex 7720 North Dobson, L.L.C., an Arizona limited liability
company, and Medicis Pharmaceutical Corporation, dated as of July 26, 2006(42)10.52
    
    
    Corporate Integrity Agreement between the Office of Inspector General of the department of
Health and Human Services and Medicis Pharmaceutical Corporation(44)10.53
    *
    
    Collaboration Agreement, dated as of August 23, 2007, by and between Ucyclyd Pharma, Inc. and
Hyperion Therapuetics, Inc.(47)10.54
    
    
    Employment Agreement, dated December 23, 2008, by and between the Company and Joseph P.
Cooper (50)10.55
    
    
    Amended and Restated Employment Agreement, dated December 23, 2008, by and between the
Company and Jason D. Hanson(50)10.56
    
    
    Employment Agreement, dated December 23, 2008, by and between the Company and Vincent P.
Ippolito (50)10.57
    
    
    Employment Agreement, dated December 23, 2008, by and between the Company and Richard D.
Peterson (50)10.58
    
    
    Amended and Restated Employment Agreement, dated December 23, 2008, by and between the
Company and Mark A. Prygocki (50)10.59
    
    
    Amended and Restated Employment Agreement, dated December 23, 2008, by and between the
Company and Mitchell S. Wortzman, Ph.D. (50)10.60
    
    
    Fourth Amendment to Employment Agreement, dated December 23, 2008, by and between the Company
and Jonah Shacknai (50)10.61
    +*
    
    Joint Development Agreement, dated as of November 26, 2008, between the Company and Impax
Laboratories, Inc.10.62
    *
    
    License and Settlement Agreement, dated as of November 26, 2008, between the Company and
Impax Laboratories, Inc.12
    
    
    Computation of Ratios of Earnings to Fixed Charges21.1
    
    
    Subsidiaries23.1
    
    
    Consent of Independent Registered Public Accounting Firm24.1
    
    
    Power of Attorney See signature page to the Companys Annual Report on Form 10-K for the
fiscal year ended December 31, 2008, as filed with the Securities and Exchange Commission on
March 2, 2009.31.1
    +
    
    Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the
Securities Exchange Act, as amended31.2
    +
    
    Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the
Securities Exchange Act, as amended32.1
    
    
    Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 200232.2
    
    
    Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
 
 +
    
    Filed herewith
    
    Previously filed with the Companys Annual Report on Form 10-K for the fiscal year ended
December 31, 2008, as filed with the Securities and Exchange Commission on March 2, 2009.*
    
    Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request
for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934.(1)
    
    Incorporated by reference to the Registration Statement on Form S-1 of the Registrant,
File No. 33-32918, filed with the SEC on January 16, 1990(2)
    
    Incorporated by reference to the Registration Statement on Form S-1 of the Company, File
No. 33-54276, filed with the SEC on June 11, 1993(3)
    
    Incorporated by reference to the Companys Annual Report on Form 10-K for the fiscal year
ended June 30, 1993, File No. 0-18443, filed with the SEC on October 13, 1993(4)
    
    Incorporated by reference to the Companys Annual Report on Form 10-K for the fiscal year
ended June 30, 1995, File No. 0-18443, previously filed with the SEC (the 1994 Form 10-K)(5)
    
    Incorporated by reference to the Companys 1995 Form 10-K 6




---



##### Table of Contents



(6)
    
    Incorporated by reference to the Companys 1995 Form 10-K(7)
    
    Incorporated by reference to the Companys 1995 Form 10-K(8)
    
    Incorporated by reference to the Companys Annual Report on Form 10-K for the fiscal year
ended June 30, 1996, File No. 0-18443, previously filed with the SEC(9)
    
    Incorporated by reference to the Companys Quarterly Report on Form 10-Q for the quarter
ended March 31, 1997, File No. 0-18443, previously filed with the SEC(10)
    
    Incorporated by reference to the Companys Quarterly Report on Form 10-Q for the quarter
ended December 31, 1996, File No. 0-18443, previously filed with the SEC(11)
    
    Incorporated by reference to the Companys Current Report on Form 8-K filed with the SEC
on December 15, 1997(12)
    
    Incorporated by reference to the Companys Quarterly Report on Form 10-Q for the quarter
ended December 31, 1998, File No. 0-18443, previously filed with the SEC(13)
    
    Incorporated by reference to the Companys Current Report on Form 8-K filed with the SEC
on July 13, 2006(14)
    
    Incorporated by reference to the Companys Annual Report on Form 10-K for the fiscal year
ended June 30, 1999, File No. 0-18443, previously filed with the SEC(15)
    
    Incorporated by reference to the Companys Quarterly Report on Form 10-Q for the quarter
ended March 31, 2001, File No. 0-18443, previously filed with the SEC(16)
    
    Incorporated by reference to the Companys Annual Report on Form 10-K for the fiscal year
ended June 30, 2001, File No. 0-18443, previously filed with the SEC(17)
    
    Incorporated by reference to the Companys Current Report on Form 8-K filed with the SEC
on October 2, 2001(18)
    
    Incorporated by reference to the Companys registration statement on Form 8-A12B/A filed
with the SEC on June 4, 2002(19)
    
    Incorporated by reference to the Companys Current Report on Form 8-K filed with the SEC
on June 6, 2002(20)
    
    Incorporated by reference to the Companys Annual Report on Form
10-K for the fiscal year ended June 30, 2002, File No. 0-18443, previously filed with the
SEC(21)
    
    Incorporated by reference to the Companys Current Report on Form
8-K filed with the SEC on March 10, 2003(22)
    
    Incorporated by reference to the Companys Quarterly Report on
Form 10-Q for the quarter ended December 31, 2003, File No. 0-18443, previously filed with
the SEC(23)
    
    Incorporated by reference to the Companys Annual Report on Form
10-K for the fiscal year ended June 30, 2004, File No. 0-18443, previously filed with the
SEC(24)
    
    Incorporated by reference to the Companys Current Report on Form
8-K filed with the SEC on March 21, 2005(25)
    
    Incorporated by reference to the Companys Quarterly Report on
Form 10-Q for the quarter ended March 31, 2005, File No. 0-18443, previously filed with the
SEC(26)
    
    Incorporated by reference to the Companys Current Report on
Form 8-K filed with the SEC on August 18, 2005(27)
    
    Incorporated by reference to the Companys Annual Report on
Form 10-K for the fiscal year ended June 30, 2005, File No. 0-18443, previously filed with
the SEC(28)
    
    Incorporated by reference to the Companys Current Report on
Form 8-K filed with the SEC on October 20, 2005(29)
    
    Incorporated by reference to the Companys Annual Report on
Form 10-K/A for the fiscal year ended June 30, 2005, File No. 0-18443, previously filed with
the
SEC on October 28, 2005(30)
    
    Incorporated by reference to the Companys Quarterly Report on
Form 10-Q for the quarter ended September 30, 2005, File No. 0-18443, previously filed with
the SEC(31)
    
    Incorporated by reference to the Companys Current Report on
Form 8-K filed with the SEC on December 13, 2005(32)
    
    Incorporated by reference to the Companys Current Report on
Form 8-K filed with the SEC on January 3, 2006(33)
    
    Incorporated by reference to Appendix 1 to the Companys definitive Proxy Statement for
the 1998 Annual
Meeting of Stockholders filed with the SEC on December 2, 1998(34)
    
    Incorporated by reference to Appendix 2 to the Companys definitive Proxy Statement for
the 1996 Annual
Meeting of Stockholders filed with the SEC on October 23, 1996 7




---



##### Table of Contents



(35)
    
    Incorporated by reference to Exhibit B to the Companys definitive Proxy Statement for
the 1992 Annual
Meeting of Stockholders previously filed with the SEC(36)
    
    Incorporated by reference to the Companys Annual Report on Form 10-K/T for the six month
transition
period ended December 31, 2005, File No. 0-18443, previously filed with the SEC on March 16,
2006(37)
    
    Incorporated by reference to the Companys Current Report on
Form 8-K filed with the SEC on March 16, 2006(38)
    
    Incorporated by reference to the Companys Quarterly Report on
Form 10-Q for the quarter ended March 31, 2006, File No. 0-18443, previously filed with the
SEC(39)
    
    Incorporated by reference to Appendix A to the Companys Definitive Proxy Statement for
the 2006
Annual Meeting of Stockholders filed with the SEC on April 13, 2006(40)
    
    Incorporated by reference to the Companys Current Report on
Form 8-K filed with the SEC on July 31, 2006(41)
    
    Incorporated by reference to the Companys Quarterly Report on
Form 10-Q for the quarter ended June 30, 2006, File No. 0-18443, previously filed with
the SEC(42)
    
    Incorporated by reference to the Companys Quarterly Report on
Form 10-Q for the quarter ended September 30, 2006, File No. 0-18443, previously filed
with the SEC(43)
    
    Incorporated by reference to the Companys Current Report on
Form 8-K filed with the SEC on February 18, 2009(44)
    
    Incorporated by reference to the Companys Current Report on
Form 8-K filed with the SEC on April 30, 2007(45)
    
    Incorporated by reference to Appendix A to the Companys Definitive Proxy Statement on
Schedule 14A filed with the SEC on April 16, 2007(46)
    
    Incorporated by reference to the Companys Registration Statement on Form S-8 dated
September 3, 2007(47)
    
    Incorporated by reference to the Companys Quarterly Report on Form 10-Q for the quarter
ended
September 30, 2007, File No. 0-18443, previously filed with the SEC(48)
    
    Incorporated by reference to the Companys Annual Report on
Form 10-K for the year ended December 31, 2007, File No. 0-18443, previously filed with the
SEC(49)
    
    Incorporated by reference to the Companys Quarterly Report on Form 10-Q for the quarter
ended June 30, 2008, File No. 001-14471, previously filed with the SEC.(50)
    
    Incorporated by reference to the Companys Current Report on Form 8-K filed with the SEC
on December 30, 2008 8




---



##### Table of Contents



SIGNATURES
   MEDICIS PHARMACEUTICAL CORPORATIONBy:
    /s/ RICHARD D. PETERSONRichard D. PetersonExecutive Vice President, Chief Financial Officer and Treasurer 9